No Data
No Data
No Data
No Data
No Data
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
We are privileged to welcome Juliette to our management team as CBO," said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.
GlobeNewswireApr 1 20:00
ANGI, MLKN and KOD Are Among After Hour Movers
Seeking AlphaMar 28 04:50
NewAmsterdam Pharma to Present New Analysis From the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination With Ezetimibe at 2024 American College of Cardiology Congress
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical co
GlobeNewswireMar 25 20:00
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients With HeFH And/or ASCVD
-- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination ("FDC") as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD ri
GlobeNewswireMar 12 20:00
NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations
Yahoo FinanceMar 1 18:14
NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress
Yahoo FinanceFeb 28 21:33
No Data
No Data